肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2013年
4期
265-268
,共4页
许晓强%白林海%邢志华%张巧花
許曉彊%白林海%邢誌華%張巧花
허효강%백림해%형지화%장교화
淋巴瘤,大B-细胞,弥漫性%T淋巴细胞亚群%血管内皮细胞生长因子
淋巴瘤,大B-細胞,瀰漫性%T淋巴細胞亞群%血管內皮細胞生長因子
림파류,대B-세포,미만성%T림파세포아군%혈관내피세포생장인자
Lymphoma,large B-cell,diffuse%T-lymphocyte subsets%Vascular endothelial growth factor
目的 探讨弥漫大B细胞淋巴瘤(DLBCL)患者外周血T细胞亚群及血清中可溶性白细胞介素2受体(sIL-2R)、血管内皮生长因子(VEGF)、乳酸脱氢酶(LDH)水平的改变及其与细胞免疫功能、临床分期及疾病进展的关系.方法 运用流式细胞术检测35例患者及20名健康人外周血T细胞亚群,ELISA法测定外周血清中sIL-2R及VEGF的水平,速率法测定血清中LDH的含量.结果 DLBCL患者血清CD4+、NK细胞数及CD4+/CD8+比值均低于健康对照[(68.62±12.82)％比(73.00±6.12)％,(14.28±7.93)％比(39.49±12.01)％,(1.03±0.84)比(1.45±0.28),均P＜0.05].DLBCL患者血清sIL-2R明显高于健康对照[(501.50±157.70) μg/L比(128.30±82.40) μg/L,P＜ 0.001],DLBCLⅢ～Ⅳ期患者血清sIL-2R水平高于Ⅰ～Ⅱ期[(618.38±192.22) μg/L比(432.45±75.48) μg/L,P＜0.05],DLBCL有B症状患者血清sIL-2R水平高于有A症状患者[(616.50±183.03) μg/L比(441.52±103.48) μg/L,P＜ 0.01].DLBCL患者血清VEGF、LDH水平均高于健康对照[(304.03±163.05)pg/ml比(156.25±47.83) pg/ml,(300.74±300.91)U/L比(177.00±32.14)U/L,均P＜ 0.05].血清sIL-2R的高表达与CD4+/CD8+比值低相关(r=0.4635,P＜ 0.05),与血清高表达VEGF、LDH有相关性(r分别为0.447、0.448,均P＜ 0.05).结论 DLBCL高表达sIL-2R与细胞免疫功能低下、体内肿瘤负荷、疾病进展及侵袭过程密切相关.
目的 探討瀰漫大B細胞淋巴瘤(DLBCL)患者外週血T細胞亞群及血清中可溶性白細胞介素2受體(sIL-2R)、血管內皮生長因子(VEGF)、乳痠脫氫酶(LDH)水平的改變及其與細胞免疫功能、臨床分期及疾病進展的關繫.方法 運用流式細胞術檢測35例患者及20名健康人外週血T細胞亞群,ELISA法測定外週血清中sIL-2R及VEGF的水平,速率法測定血清中LDH的含量.結果 DLBCL患者血清CD4+、NK細胞數及CD4+/CD8+比值均低于健康對照[(68.62±12.82)％比(73.00±6.12)％,(14.28±7.93)％比(39.49±12.01)％,(1.03±0.84)比(1.45±0.28),均P＜0.05].DLBCL患者血清sIL-2R明顯高于健康對照[(501.50±157.70) μg/L比(128.30±82.40) μg/L,P＜ 0.001],DLBCLⅢ～Ⅳ期患者血清sIL-2R水平高于Ⅰ～Ⅱ期[(618.38±192.22) μg/L比(432.45±75.48) μg/L,P＜0.05],DLBCL有B癥狀患者血清sIL-2R水平高于有A癥狀患者[(616.50±183.03) μg/L比(441.52±103.48) μg/L,P＜ 0.01].DLBCL患者血清VEGF、LDH水平均高于健康對照[(304.03±163.05)pg/ml比(156.25±47.83) pg/ml,(300.74±300.91)U/L比(177.00±32.14)U/L,均P＜ 0.05].血清sIL-2R的高錶達與CD4+/CD8+比值低相關(r=0.4635,P＜ 0.05),與血清高錶達VEGF、LDH有相關性(r分彆為0.447、0.448,均P＜ 0.05).結論 DLBCL高錶達sIL-2R與細胞免疫功能低下、體內腫瘤負荷、疾病進展及侵襲過程密切相關.
목적 탐토미만대B세포림파류(DLBCL)환자외주혈T세포아군급혈청중가용성백세포개소2수체(sIL-2R)、혈관내피생장인자(VEGF)、유산탈경매(LDH)수평적개변급기여세포면역공능、림상분기급질병진전적관계.방법 운용류식세포술검측35례환자급20명건강인외주혈T세포아군,ELISA법측정외주혈청중sIL-2R급VEGF적수평,속솔법측정혈청중LDH적함량.결과 DLBCL환자혈청CD4+、NK세포수급CD4+/CD8+비치균저우건강대조[(68.62±12.82)％비(73.00±6.12)％,(14.28±7.93)％비(39.49±12.01)％,(1.03±0.84)비(1.45±0.28),균P＜0.05].DLBCL환자혈청sIL-2R명현고우건강대조[(501.50±157.70) μg/L비(128.30±82.40) μg/L,P＜ 0.001],DLBCLⅢ～Ⅳ기환자혈청sIL-2R수평고우Ⅰ～Ⅱ기[(618.38±192.22) μg/L비(432.45±75.48) μg/L,P＜0.05],DLBCL유B증상환자혈청sIL-2R수평고우유A증상환자[(616.50±183.03) μg/L비(441.52±103.48) μg/L,P＜ 0.01].DLBCL환자혈청VEGF、LDH수평균고우건강대조[(304.03±163.05)pg/ml비(156.25±47.83) pg/ml,(300.74±300.91)U/L비(177.00±32.14)U/L,균P＜ 0.05].혈청sIL-2R적고표체여CD4+/CD8+비치저상관(r=0.4635,P＜ 0.05),여혈청고표체VEGF、LDH유상관성(r분별위0.447、0.448,균P＜ 0.05).결론 DLBCL고표체sIL-2R여세포면역공능저하、체내종류부하、질병진전급침습과정밀절상관.
Objective To investigate the changes of peripheral blood T cell subsets and serum soluble interleukin-2 receptor (sIL-2R),vascular endothelial growth factor (VEGF) and LDH in patients with diffuse large B cell lymphoma,and to investigate their relationship of the cellular immune function,clinical stage and disease progression.Methods 35 cases of DLBCL patients were selected as observe group,20 cases of healthy individuals as normal control group.Peripheral blood T cell subsets were detected by flow cytometry.Serum soluble interleukin-2 receptor (sIL-2R) and vascular endothelial growth factor (VEGF) were detected by ELISA assay.Serum levels of LDH were detected by the rate method for measuring.Results The expression levels of CD4,NK cells and CD4/CD8 ratios in all patients with DLBCL were lower than healthy individuals [(68.62±12.82) ％ vs(73.00±6.12) ％,(14.28±7.93) ％ vs (39.49±12.01) ％,(1.03±0.84) vs (1.45±0.28),all P ＜ 0.05].Serum sIL-2R in patients with DLBCL was significantly higher than healthy individuals [(501.50±157.70).μg/L vs (128.30±82.40) μg/L,P＜ 0.001].Serum levels of sIL-2R with Ⅲ-Ⅳ stage in patients with DLBCL was higher than that in ones with Ⅰ-Ⅱ stage [(618.38±192.22) μg/L vs (432.45±75.48)μg/L,P ＜ 0.05].Serum expression levels of sIL-2R in patients with DLBCL with B symptoms was higher than that in ones with A symptoms [(616.50±183.03) μg/L vs (441.52±103.48) μg/L,P ＜ 0.01].The expression levels of VEGF,LDH in patients with DLBCL were higher than healthy individuals [(304.03±163.05) pg/ml vs (156.25±47.83) pg/ml,(300.74±300.91) U/L vs (177.00±32.14) U/L,both P ＜ 0.05].The high expression level of serum sIL-2R was correlated with low CD4/CD8 ratio (r =0.4635,P ＜ 0.05).The high expression levels of serum sIL-2R was correlated with the high expression levels of serum VEGF,LDH (r =0.447,P ＜ 0.05; r =0.448,P ＜ 0.05).Conclusion High expression levels of serum sIL-2R in DLBCL are closely associated to low cellular immune function,tumor burden in vivo,disease progression and invasion.
